A recent study suggested that CDK4/6 inhibitors could downregulate DNMT1 expression in Treg cells and trigger anti‐tumor immunity,76 suggesting that targeting PAX6 might be of clinical value to tumor immunotherapy in the future. The gene discussed is PAX6; the disease is neoplasm.